Market Cap 2.92B
Revenue (ttm) 661.82M
Net Income (ttm) 73.87M
EPS (ttm) N/A
PE Ratio 19.34
Forward PE 30.07
Profit Margin 11.16%
Debt to Equity Ratio 0.00
Volume 840,100
Avg Vol 706,264
Day's Range N/A - N/A
Shares Out 56.07M
Stochastic %K 92%
Beta 0.78
Analysts Strong Sell
Price Target $54.20

Company Profile

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatm...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 301 838 2500
Address:
9715 Key West Avenue, Rockville, United States
IN0V8
IN0V8 Oct. 23 at 3:22 PM
$SUPN Opportunity TD Cowen raises target price to $60 from $45
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 3:20 PM
TD Cowen has adjusted their stance on Supernus Pharmaceuticals ( $SUPN ), setting the rating to Buy with a target price of 45 → 60.
0 · Reply
nikitatrades
nikitatrades Oct. 9 at 4:54 PM
Piper Sandler upgrades $SUPN to Overweight and raises its price target to $65 from $40. The boost is driven by excitement over its new Onapgo pump for Parkinson's disease, seen as a major profit driver. 💊
0 · Reply
JarvisFlow
JarvisFlow Oct. 9 at 11:54 AM
Piper Sandler has updated their rating for Supernus Pharmaceuticals ( $SUPN ) to Overweight with a price target of 65.
0 · Reply
jdlman
jdlman Oct. 9 at 11:20 AM
0 · Reply
hawkmdend
hawkmdend Oct. 3 at 3:43 PM
$CING I have to add $COLL as a potential buyer/partner. The new Chief Legal Officer, Nilay Patel, comes from Ironshore Pharm, which Collegium acquired to expand its presence in the ADHD/CNS space. This is getting very interesting… my Money is with COLL or $SUPN. I'm done with my DD. Happy trading, nothing else to add.
1 · Reply
hawkmdend
hawkmdend Oct. 3 at 2:52 PM
$CING IMO, Cingulate is for sale. The latest moves by Bod/executives are telling the story. COO out, Expert in deals hired-CLO( check Ironshore Pharm-Buyout), problematic CEO out, Interim CFO-CEO. The ADHD market is too lucrative for current players in the CNS space to let a new player capture a significant portion of their market share. Who in the CNS space could be the buyer? I will go with $SUPN, Otsuka, or maybe a division of JNJ. Anyone with other potential players?
2 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 4:21 PM
$SUPN: Unusual Options Activity Alerted CALL flow observed 203x contracts at Strike price of $48 Exp on 11/21/2025 with Premium of $81K and showing BEARISH Sentiment
0 · Reply
IN0V8
IN0V8 Sep. 29 at 6:30 PM
$SUPN Jefferies raises target price to $55 from $45
0 · Reply
txbondman
txbondman Sep. 29 at 2:25 PM
sld some stocks (partial) to raise cash. sld $BABA for a 115% gain; sld $CIEN for a 200% gain; sld $MPWR for a 130% gain; sld $ROKU for a 45% loss; sld $SUPN for a 105% gain;
0 · Reply
Latest News on SUPN
Supernus Pharmaceuticals: Heading In The Right Direction

Sep 17, 2025, 4:05 PM EDT - 5 weeks ago

Supernus Pharmaceuticals: Heading In The Right Direction


Supernus Announces Second Quarter 2025 Financial Results

Aug 5, 2025, 4:05 PM EDT - 2 months ago

Supernus Announces Second Quarter 2025 Financial Results


Supernus Announces Paragraph IV ANDA Filings for Qelbree®

May 28, 2025, 4:05 PM EDT - 5 months ago

Supernus Announces Paragraph IV ANDA Filings for Qelbree®


Supernus Announces First Quarter 2025 Financial Results

May 6, 2025, 4:08 PM EDT - 6 months ago

Supernus Announces First Quarter 2025 Financial Results


Supernus to Participate in Two Upcoming Investor Conferences

Mar 4, 2025, 4:30 PM EST - 8 months ago

Supernus to Participate in Two Upcoming Investor Conferences


IN0V8
IN0V8 Oct. 23 at 3:22 PM
$SUPN Opportunity TD Cowen raises target price to $60 from $45
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 3:20 PM
TD Cowen has adjusted their stance on Supernus Pharmaceuticals ( $SUPN ), setting the rating to Buy with a target price of 45 → 60.
0 · Reply
nikitatrades
nikitatrades Oct. 9 at 4:54 PM
Piper Sandler upgrades $SUPN to Overweight and raises its price target to $65 from $40. The boost is driven by excitement over its new Onapgo pump for Parkinson's disease, seen as a major profit driver. 💊
0 · Reply
JarvisFlow
JarvisFlow Oct. 9 at 11:54 AM
Piper Sandler has updated their rating for Supernus Pharmaceuticals ( $SUPN ) to Overweight with a price target of 65.
0 · Reply
jdlman
jdlman Oct. 9 at 11:20 AM
0 · Reply
hawkmdend
hawkmdend Oct. 3 at 3:43 PM
$CING I have to add $COLL as a potential buyer/partner. The new Chief Legal Officer, Nilay Patel, comes from Ironshore Pharm, which Collegium acquired to expand its presence in the ADHD/CNS space. This is getting very interesting… my Money is with COLL or $SUPN. I'm done with my DD. Happy trading, nothing else to add.
1 · Reply
hawkmdend
hawkmdend Oct. 3 at 2:52 PM
$CING IMO, Cingulate is for sale. The latest moves by Bod/executives are telling the story. COO out, Expert in deals hired-CLO( check Ironshore Pharm-Buyout), problematic CEO out, Interim CFO-CEO. The ADHD market is too lucrative for current players in the CNS space to let a new player capture a significant portion of their market share. Who in the CNS space could be the buyer? I will go with $SUPN, Otsuka, or maybe a division of JNJ. Anyone with other potential players?
2 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 4:21 PM
$SUPN: Unusual Options Activity Alerted CALL flow observed 203x contracts at Strike price of $48 Exp on 11/21/2025 with Premium of $81K and showing BEARISH Sentiment
0 · Reply
IN0V8
IN0V8 Sep. 29 at 6:30 PM
$SUPN Jefferies raises target price to $55 from $45
0 · Reply
txbondman
txbondman Sep. 29 at 2:25 PM
sld some stocks (partial) to raise cash. sld $BABA for a 115% gain; sld $CIEN for a 200% gain; sld $MPWR for a 130% gain; sld $ROKU for a 45% loss; sld $SUPN for a 105% gain;
0 · Reply
SweepCastApp
SweepCastApp Sep. 29 at 2:50 AM
$SUPN: Unusual Options Activity Alerted CALL flow observed 200x contracts at Strike price of $48 Exp on 11/21/2025 with Premium of $68K and showing BULLISH Sentiment
0 · Reply
Doozio
Doozio Sep. 20 at 2:40 PM
$SUPN thing about MNDY 🐑 lows and tight weekly closes. $SYM thing about Roger coming out of the tightness and $SMMT thing about potential tightness bahhhhtom of the base 🐒🍌🧠⏰♾️
2 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 10 at 11:41 AM
$SUPN Great piece that accurately captures SUPN's current position. So if you want to refresh your understanding of SUPN or learn about SUPN for the first time, this is essential reading. https://beyondspx.com/quote/SUPN/analysis/supernus-pharmaceuticals-a-new-growth-epoch-ignites-with-strategic-expansion-and-pipeline-power-nasdaq-supn
0 · Reply
JarvisFlow
JarvisFlow Aug. 29 at 1:19 PM
Piper Sandler updates rating for Supernus Pharmaceuticals ( $SUPN ) to Neutral, target set at 36 → 40.
0 · Reply
nostic
nostic Aug. 26 at 6:31 PM
$CGTX let's do some "get to know'em" DD while we wait for news and a reversal... Who is Jack Khattar? He is Board Chair for CGTX. He is also CEO of Supernus Pharmaceuticals ($SUPN), which has a market cap of $2.5B. They are a commercial stage biotech company with several drugs to treat Parkinsons, ADHD, and postpartum depression (clinical stage). SUPN has grown revenues from $147M in 2015 to $662M in 2024. He's been on the CGTX board for +4 years and holds a MBA from Wharton. Quiver Quantitative estimates he has a personal net worth of $113M. He is also board chair for scPharmaceuticals. Mr. Khattar strikes me as a sharp and prudent CEO, and it's great to see people like him on the bridge here.
4 · Reply
GueroMoonshot
GueroMoonshot Aug. 21 at 1:32 AM
$SUPN looking super
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Aug. 17 at 5:53 PM
Commercial-stage bio (oncology & non-oncology) actual Q2 2025 revenues versus consensus. We track 29 of the 35 oncology focused bios in this peer group & exclude those like $MRUS where we believe pipelines are the primary drivers of value potential (of course some may disagree) & all non-oncology with 1st approvals since 1/1/2017. In non-oncology, it is interesting to note the more mature bios like $ALKS & $SUPN and/or those with nearing patent expirations like $HRMY trade at lower multiples of actual Q2 25 revenues. Note Q2 2025 revenues may include non-recurring or one-time sales. Its our subjective opinion $IONS had the most impressive beat & raise (at least v. expectations 3 months ago). This is not investment advice. We're merely sharing our data tracker.
2 · Reply
txbondman
txbondman Aug. 6 at 2:40 PM
sld some winners (partial) to take profits. sld $MPWR for a 105% gain; sld $SUPN for an 80% gain; sld $THRM for a 35% gain;
0 · Reply
mikesterz7
mikesterz7 Aug. 5 at 8:48 PM
$SUPN 🚨 Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, respectively. Net sales of GOCOVRI of $36.7 million and $67.4 million in the second quarter and first six months of 2025, respectively. Total revenues were $165.5 million and $315.3 million for the three and six months ended June 30, 2025. Operating income of $12.1 million and $1.9 million for the three and six months ended June 30, 2025, respectively. Adjusted operating earnings (non-GAAP)(1) were $40.9 million and $66.9 million for the three and six months ended June 30, 2025, respectively. Completed acquisition of Sage Therapeutics, Inc. (Sage) on July 31, 2025. Increasing full year 2025 revenue guidance and updating full year 2025 operating earnings (loss) guidance to reflect strong first-half 2025 performance and the Sage acquisition.
0 · Reply
DonCorleone77
DonCorleone77 Aug. 5 at 8:42 PM
$SUPN Supernus reports Q2 EPS 40c vs. 36c last year -- Q2 revenue $165.5M, consensus $154.08M. -- Raises FY25 revenue view $670M-$700M from $600M-$630M, consensus $636.35M.
0 · Reply
Whiskey1679
Whiskey1679 Aug. 5 at 8:19 PM
Whiskeys Penny Picks out tomorrow! Trending: $SUPN $SWKS $ANGI $IXHL $ABP
0 · Reply
Doozio
Doozio Aug. 5 at 2:02 PM
$SYM thing $SUPN $SMMT ing special about 🐒🍌🧠⏰♾️
0 · Reply